The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated longterm control of metastatic melanoma in a fraction of patients. Although ipilimumab undoubtedly exerts its therapeutic effects via immunostimulation, thus far clinically useful, immunologically relevant biomarkers that predict treatment efficiency have been elusive. Here, we show that neutralization of IL-2 or blocking the α and β subunits of the IL-2 receptor (CD25 and CD122, respectively) abolished the antitumor effects and the accompanying improvement of the ratio of intratumoral T effector versus regulatory cells (Tregs), which were otherwise induced by CTLA-4 blockade in preclinical mouse models. CTLA-4 blockade led to the reduction of a suppressive CD4 + T cell subset expressing Lag3, ICOS, IL-10 and Egr2 with a concomitant rise in IL-2-producing effector cells that lost FoxP3 expression and accumulated in regressing tumors. While recombinant IL-2 improved the therapeutic efficacy of CTLA-4 block-
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Introduction
The concept of cancer immune surveillance and editing, originally coined by Burnet and Thomas and then proven by Schreiber's group in mice [1] , paved the way to the clinical demonstration of the relevance of intratumoral effector memory Th1 or Tc1 cells to the prognosis of human malignancies [2] . Measures designed to induce cellular anticancer immune responses and to promote the influx of specific T lymphocytes into tumor beds may constitute a valid strategy for prolonging patient survival. Multiple T cell co-stimulatory and co-inhibitory receptors act in concert to regulate the activation, proliferation and effector functions of T lymphocytes. CD28 and CTLA-4 are among the best characterized T cell co-stimulatory and co-inhibitory molecules, respectively [3] . Both molecules are expressed on the surface of selected T populations and transmit opposing signals upon interaction with their ligands, CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells [3] .
The CTLA-4 blocking antibody ipilimumab was approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) in 2011 for the treatment of advanced metastatic melanoma (MM) after the publication of two phase III clinical trials showing its capacity to prolong overall survival of patients with advanced MM [4, 5] . However, only a fraction of MM patients exhibited a long-term benefit from ipilimumab treatment. This fact, coupled to the close-to-prohibitive costs and major side effects of this therapeutic regimen, has spurred interest in the discovery of biomarkers that would predict the efficacy of ipilimumab. A number of preclinical studies have defined (some of) the basic mechanisms underlying the activity of this first-in-class product. Blocking the interaction between CTLA-4 and its known ligands B7-1 and B7-2 reverses intrinsic and extrinsic inhibitory effects of CTLA-4 on T cell functions [6, 7] , thus leading to enhanced T cell proliferation, cytokine production and intratumoral accumulation of effector CD4 + and CD8 + T cells. CTLA-4 inhibits interade, the decoy IL-2 receptor α (IL-2Rα, sCD25) inhibited the anticancer effects of CTLA-4 blockade. In 262 metastatic melanoma patients receiving ipilimumab, baseline serum concentrations of sCD25 represented an independent indicator of overall survival, with high levels predicting resistance to therapy. Altogether, these results unravel a role for IL-2 and IL-2 receptors in the anticancer activity of CTLA-4 blockade. Importantly, our study provides the first immunologically relevant biomarker, namely elevated serum sCD25, that predicts resistance to CTLA-4 blockade in patients with melanoma. leukin-2 (IL-2) transcription in CD4 + T lymphocytes [6, 8] , which is likely due to its ability to stimulate TGF-β release by CD4 + T cells [9] . Moreover, knockout or neutralization of CTLA-4 inhibits Treg function [10, 11] , and antibody-dependent cell-mediated cytotoxicity (ADCC) or opsonization mediated by anti-CTLA-4 antibodies may favor the elimination of intratumoral regulatory T cells (Tregs) [12] . CTLA-4 blockade improves the ratio of intratumoral effector T cells to Tregs, when combined with tumor vaccines [13, 14] , indoleamine 2,3-dioxygenase (IDO) inhibitors [15] or chemotherapeutic agents [16] .
Several pharmacodynamic markers of ipilimumab bioactivity have been reported. In MM patients, ipilimumab treatment increased the absolute lymphocyte count [17] and the frequencies of circulating HLA-DR + or ICOS + T cells [18, 19] . An increase in the absolute eosinophil count has also been associated to clinical benefit [17] .
Yuan et al. [20] showed multifunctional T and B cell responses directed against the prominent tumor antigen NY-ESO-1 in a fraction of responding patients. The ratio of tumor-infiltrating CD8 + T effector cells to FoxP3 + Tregs after ipilimumab infusion was tightly correlated with the extent of tumor shrinkage in MM and ovarian cancer patients [18, 21] . This correlation between a high CD8 + T effector/Treg ratio and tumor regression has been observed in patients treated with the human IgG1 ipilimumab (which mediates ADCC) but less frequently in those treated with the IgG2 tremelimumab [22, 23] . CD4 + ICOS high IFNγ + T cells recognizing tumor epitopes were found after radical prostatectomy in prostate cancers and non-malignant tissues post-neoadjuvant ipilimumab [24] . Finally, correlations between therapy-induced antibody responses and tumor regression have been reported in advanced ovarian and melanoma patients. Dranoff's group reported that patients responding to GM-CSF-expressing tumor cell-based vaccine (GVAX) treatment followed by ipilimumab infusions generated high titers of antibodies against MHC class I-related chain A (MICA) that antagonized the immune suppression evoked by soluble MICA and stimulated innate and adaptive antitumor cytotoxicity [25] .
CTLA-4 blockade in cancer might unleash preexisting or vaccine-induced antitumor effector and/or memory T cell activities from inhibition. Thus, anti-CTLA-4 may function best in the subset of patients with high levels of tumor-infiltrating lymphocytes (TILs) and intratumoral Tregs [22, 26] , low serum level of VEGF [27] and preexisting responses to tumor antigens such as NY-ESO-1 [20] . However, large prospective studies demonstrating the clinical utility of baseline markers that can predict CTLA-4 blockade effectiveness (as opposed to a pharmacokinetic/dynamic parameters) are still ongoing.
Driven by these considerations, we explored the mechanism underlying the action of CTLA-4 blockade, hoping to identify clinically useful biomarkers that predict the treatment efficiency. We focused on the IL-2/IL-2 receptor (IL-2R) system due to its potential role in the action of ipilimumab. Indeed, one study performed in mice revealed an essential role of IL-2 in mediating the antitumor activity of CTLA-4 blockade [28] . Moreover, a clinical trial showed that the therapeutic effects of CTLA-4 blockade against melanoma were not improved by simultaneous treatment with recombinant IL-2 (rIL-2) [29] , suggesting that both treatments may act through the same pathway. Our results here uncover a key role for IL-2 and several components of the IL-2R complex (CD25 and CD122) in the antitumor effects of anti-CTLA-4 antibodies in murine colon cancer and sarcoma models. Neutralization of CD122 abolished the effects of CTLA4 blockade in elevating intratumoral CD4 + and CD8 + T effector/Treg ratios. The main source of IL-2 was the immunosuppressive CD4 + T cell subset expressing Lag3, Egr2, IL-10, ICOS and FoxP3, which was converted into or was replaced by an IL-2-producing FoxP3-negative T cell population accumulating in tumor beds upon blockade of mouse CTLA-4 (mCTLA-4). Hence, the efficacy of mCTLA-4 blockade was significantly potentiated by rIL-2 or anti-IL-10R and anti-Lag3 (but not ICOS) neutralizing antibodies in mice. A single infusion of ipilimumab triggered an increase in circulating levels of soluble CD25 (sCD25) and Lag3 in MM patients. High levels of sCD25, which was reported to act as a decoy receptor [30, 31] , were detrimental for the anticancer activity of anti-mCTLA-4 Ab and ipilimumab in mice and patients, respectively. The best multivariate model calculated based on nine cohorts of 262 MM patients suggests that individuals with sCD25 high LDH high serum signatures at diagnosis are less likely to benefit from ipilimumab therapy than those with low pre-treatment levels of sCD25.
Results
IL-2/IL-2Rαβ-dependent antitumor effects of anti-mCT-
LA-4 therapy
Several cytokine-related signaling pathways may affect the host-tumor equilibrium in advanced human malignancies [32] [33] [34] . We therefore investigated the putative contribution of two critical cytokine receptors, the IL-2R and the type I interferon receptor (IFNAR1), to the antitumor effects of CTLA4 blockade. These effects were evaluated in two preclinical models, MCA205 sarcomas and MC38 colon cancers that were both engineered to express the model antigen ovalbumin (OVA). While IFNAR1 was dispensable for the anticancer activity of anti-mCTLA-4 Ab (Supplementary information, Figure  S1A ), components of the IL-2R-related signaling pathway were required for the antitumor effects of mCTLA-4 blockade ( Figure 1A-1D ). Antibody-mediated neutralization of the two interleukins that bind to the IL-2Rβγ complex, IL-2 and IL-15, as well as that of two IL-2R subunits, IL-2Rα (CD25) and IL-2Rβ (CD122), reduced the efficacy of mCTLA-4 blockade in both tumor models (except for the effects of anti-CD25, which were only examined in the MCA205-OVA model; Figure 1A-1D) . Blockade of the IL-2Rα chain was accompanied by the loss of effector CD4 + CD25 + FoxP3 -lymphocytes (data not shown). IL-2 is produced by activated T cells and acts on T and NK cells to amplify their proliferation and effector functions [35] . In both tumor models, we found that mCTLA-4 blockade lost its tumor growth-reducing effects upon depletion of CD4 + T cells (Supplementary information, Figure S1B ) or CD8 + T cells (Supplementary information, Figure S1C ) but not upon depletion of NK cells using NK1.1-specific or asialo-GM1-specific antibodies or upon blockade of NKG2D (Supplementary information, Figure S1D -S1F).
We next analyzed possible biomarkers predicting the efficacy of mCTLA-4 blockade in the MCA205-OVA model. For this purpose, we segregated animals exhibiting tumor stabilization after 3 inoculations of anti-mCT-LA-4 Ab (noted as responders, R) from those that failed to respond (noted as non-responders, NR) ( Figure 2A From these data, we conclude that IL-2 and its high-affinity receptor are both critical for T cell-dependent control of tumor progression induced by mCTLA-4 blockade.
CD4 + Lag3 + T cells showed upregulated IL-2 transcription upon CTLA-4 blockade
In accord with the implication of endogenous IL-2 in the action of CTLA4 blockade, and consistent with a previous work [28] , rIL-2 greatly synergized with the mCT-LA-4 Ab in terms of reducing tumor size ( Figure 3A 
Lag3
+ T cells showed downregulated ICOS expression (45% ± 10% pre-versus 20% ± 5% post-anti-mCTLA-4 Ab, data not shown) and FoxP3 expression (45% ± 20% pre-versus 15% ± 10% post-anti-mCTLA-4 Ab, Figure 3C ), which were more evident in R than NR tumors, leading to the maintenance of CD4 Altogether, CTLA-4 blockade alters the functional profile of CD4 + Lag3 + T cells, which become the major source of intratumoral IL-2. At present, it is not clear whether this results from their phenotypic conversion or may be explained by the replacement within tumor beds of one T cell population by another that lacks FoxP3 expression and produces IL-2.
sCD25 inhibits the efficacy of CTLA-4 blockade
We next monitored levels of surrogate markers of lymphocyte activation such as soluble CD25 (sCD25) and Lag3 (sLag3) in the serum of MM patients treated with ipilimumab. Similar to patients with autoimmune vasculitis receiving low-dose rIL-2 [37] , MM patients (n = 262) treated with ipilimumab (most of whom received 3 mg/kg on a compassionate basis, Supplementary information, Table S1 ) and patients with an autoimmune disease (n = 9) treated with low-dose rIL-2 exhibited a significant rise in their serum sCD25 levels ( Figure 4A -4B), as well as, though to a lesser extent, serum sLag3 levels ( Figure 4C-4D) . Similar results were obtained from a cohort of 20 MM patients treated with the alternative anti-CTLA-4 Ab, tremelimumab (3 weeks after a single dose of 15 mg/kg) ( Figure 4E ). Intriguingly, a proportion of MM patients presented high baseline levels of sCD25 (above the median of normal volunteers: 330-1 650 pg/ml [38] ). Soluble CD25 reportedly behaves as a decoy receptor or mediates immunosuppressive effects mainly via Tregs [30, 31] . Indeed, baseline concentrations of sCD25 in MM patients positively correlated with high circulating Treg numbers in a group of 27 patients whose peripheral blood mononucleated cells (PBMCs) were available [39] (Figure 4F ).
As serum sCD25 concentrations did not increase after mCTLA4 blockade in tumor-bearing mice (Supplementary information, Figure S3 ), we investigated the functional impact of artificially raising serum sCD25 concentrations through iterative systemic infusions of high doses of recombinant sCD25 ( Figure 5A , left panel). This manoeuver induced an expansion of CD4
high Tregs in the blood on day 8 ( Figure 5B ), and in the spleen on day 15 (which was more evident in the presence of mCTLA-4 blockade; Figure 5C ). External supply of sCD25 compromised the antitumor effects observed shortly after mCTLA-4 blockade ( Figure 5D -5E). Moreover, sCD25 administration impaired anti-mCT-LA-4 Ab-induced downregulation of FoxP3 expression on both Tregs (CD4 + CD25 high ) and CD4 + Lag3 + TILs ( Figure 5F ). In contrast, the elevated frequency of CD8 + ICOS + TILs induced by mCTLA-4 blockade (that was CD122-independent; Figure 2D , right panel) was not affected by sCD25 (data not shown).
Altogether, these preclinical data suggest that high circulating levels of sCD25 prior to therapy may curtail the antitumor effects of mCTLA-4 blockade.
Baseline sCD25 and lactate dehydrogenase (LDH) serum levels predict resistance to CTLA-4 blockade
The potential negative impact of a high baseline level of sCD25 on the clinical outcome of MM patients receiving ipilimumab was evaluated in a retrospective study encompassing 9 independent cohorts from 5 different countries (Supplementary information, Table S1 ). An elevated serum level of LDH is known to be a poor prognostic factor in a number of cancers including melanoma, perhaps reflecting the anaerobic glycolysis of rapidly growing hypoxic tumors. The LDH parameter has been included in the 2009 AJCC staging system for melanoma, which subdivides MM into M1a (skin, lymph node or subcutaneous metastases only), M1b (lung metastases only) and M1c (visceral metastases or metastases at any site with a raised LDH serum level) [40] . Circulating pretreatment levels of sCD25 and LDH, immune response-related criteria (irRC) at 4 weeks and tumor staging (M1a, M1b, M1c) were all statistically associated with the overall survival (OS) in univariate analyses ( Figure 6A -6B and Supplementary information, Table  S1 , Figures S4 and S5A , with S5A focusing on distinct cohorts). In contrast, neither sLAG3 levels nor absolute lymphocyte counts at diagnosis correlated with the OS (Supplementary information, Figure S5B and data not shown). The prognostic value of sCD25 remained significant (hazard ratio (HR) = 1.26 [1.04; 1.54], P < 0.0165) after including the LDH value in a multivariate model, suggesting an independent contribution of sCD25 to OS ( Figure 6C ). High sCD25 concentrations at diagnosis correlated with poor outcome, specifically in the subset with high LDH levels ( Figure 6C) . Similarly, high sCD25 levels observed 3 weeks (T21) post-ipilimumab treatment negatively predicted OS ( Figure 6D ), while the percentage raise of sCD25 at T21 with respect to T0 failed to do so (Supplementary information, Figure S5C ). We conclude that, combined with LDH values, circulating sCD25 levels represent a valuable predictor of resistance to CTLA-4 blockade.
Discussion
Biomarkers that predict the long-term effects of expensive and potentially toxic treatments with im- 
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+ live tumor-infiltrating cells. Results are presented as concatanated data from individual mice or tumors from several independent experiments. *P < 0.05, **P < 0 .01, ***P < 0.001, ns, not significant (Student's t-test or ANOVA).
mune-checkpoint blockers may be used to significantly improve the clinical and economical management of cancer patients. Here, we used a mechanism-centered approach that led to the discovery of a novel biomarker relevant to CTLA4 blockade in MM patients. In summa- Anti-ICOS and anti-LAG3 neutralizing Abs were injected i.p. 1 day before each anti-CTLA-4 treatment. IL-10R-specific neutralizing Ab was injected daily. Results are presented as mean ratios from several independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant (Student's t-test or ANOVA). T lymphocytes with a concomitant rise in IL-2-producing cells; and (iii) external supply of sCD25 subverted the therapeutic effects of CTLA-4 blockade in mice, while high baseline serum levels of sCD25 were associated with compromised ipilimumab effects in MM patients. The immunostimulatory action of mCTLA-4 blockade has been well studied [13, 41] . CTLA-4 is a critical negative regulator of antitumor immunity [41] and an essential mediator of immune homeostasis as illuminated by the fatal lymphoproliferative disorder in CTLA-4-deficient mice [42] . A pioneering report unveiled the role of IL-2 in mediating the anti-CTLA-4 Ab-induced proliferation of adoptively transferred OT-1 T cells (which express an ovalbumin-specific TCR), as well as their accumulation in the peritoneal cavity harboring OVA-expressing tumors. In this model system, CTLA-4 blockade stimulated IL-2-secreting CD4 + T helper cells, which were indispensable for the sustained effector (lytic) function of CD8 + CD25 + T cells [28] . Anti-CTLA-4-IgG2a and to a lesser extent anti-CTLA-4-IgG2b may cause the elimination of Tregs from the tumor site, consistent with their ability to bind to FcγRs [12] . This was accompanied by the activation and expansion of effector T cells, which might either result directly from alleviating inhibitory CTLA-4-B7 interactions or indirectly from Treg depletion. The functional relevance of the balance between these two antagonistic T cell subsets has been previously highlighted in mice, in the context of GVAX-based vaccines and CTLA-4 blockade against B16 melanomas, as well as in advanced ovarian carcinoma patients [18, 43] . Our data revealed that two responses that were strongly associated with tumor regression after mCTLA-4 blockade, namely the depletions of FoxP3 + Treg and CD4 + Lag3 + FoxP3 + TILs, were compromised by sCD25 treatment ( Figure 5F ). High doses of anti-CD25 depleting Ab that decreased circulating and intratumoral effector T cells [28] (data not shown) also compromised the therapeutic efficacy of CTLA-4 blockade ( Figure 1D ). Neutralizing the IL-2Rβ chain CD122 similarly abolished the rise in the Teff/Treg ratio that normally follows mCTLA-4 blockade ( Figure 2C) . Altogether, our findings support the notion that the IL-2/IL-2Rαβ signaling pathway is indispensable for facilitating the stimulation of CD4 + T helper and CD8 + T effector cells in the context of mCTLA-4 blockade.
Our results also revealed that the principal source of intratumoral IL-2 after mCTLA-4 blockade was a CD4 + T cell subset expressing Lag3. Lag3 co-engagement during TCR/CD3 ligation mediates T cell suppression [36, 44] . In accord with previous reports on intestinal CD4 + Lag3 + cells [36] , the CD4 + Lag3 + subset identified here also expressed high levels of IL-10 within tumors (data not shown). Roncarollo's group recently identified a population of IL-10-producing Tr1 cells (the CD49b + Lag3 + subset) exhibiting a strong immunosuppressive phenotype, which express high levels of CTLA-4 [45] Figure 3F) .
In addition to membrane-anchored IL-2Rα (55 kDa), a truncated soluble form of the CD25 receptor (sIL-2Rα/ sCD25) (45 kDa) efficiently binds to IL-2. sCD25 is generated as a monomeric protein from the membrane-bound form through proteolytic cleavage or 'shedding', and its serum concentration is directly related to the proliferation rate of activated T cells [38] . Elevated serum sCD25 levels have been detected in autoimmune and inflammatory diseases, as well as in cancer. In tumor-bearers, IL-2Rα is expressed on activated immune cells (lymphocytes or monocytes) and, at least in some cases, non-stimulated malignant cells. Intravenous infusion of high doses of rIL-2 for T cell activation also induces an elevation in serum sCD25 levels [47] . Similarly, our current study revealed that low doses of rIL-2 that reportedly caused Treg expansion and suppressed cryoglobulinemia-related vasculitis in patients with hepatitis C [37] elicited an increase in sCD25 serum levels comparable to that observed in patients treated with one infusion of ipilimumab ( Figure 4A-4B) . Intriguingly, low doses of ipilimumab (< 3 mg/kg, in conjunction with rGM-CSF) could promote an increase in the frequency of circulating Tregs high CD127 -Tregs of 27 MM patients were determined at diagnosis before ipilimumab therapy.
[39]. Based on these premises, it is tempting to speculate that high sCD25 serum concentrations could reflect an IL-2-mediated Treg proliferation, thus explaining the positive correlation between sCD25 levels and circulat- ing Tregs in MM patients ( Figure 4F) . The clinical relevance of serum sCD25 has been evaluated in adults and infants [38] . Highly supranormal sCD25 levels are often found in lymphoproliferative disorders. In contrast, solid malignancies usually are not associated with elevations in serum sCD25 unless the disease has disseminated [48] [49] [50] [51] . Elevated sCD25 levels in the ascites of ovarian cancer patients and in the serum of breast cancer patients correlated with a low frequency of TILs, suggesting that sCD25 could inhibit antitumor immunosurveillance [52] . sCD25 suppresses IL-2-induced surface CD25 expression and T cell responses in vitro [30, 31, [53] [54] [55] . Russell et al. [56] reported that sCD25 can exacerbate experimental autoimmune encephalitis by acting as a decoy receptor that sequesters IL-2, eventually altering the balance between Th1/Th17 and Tregs. A different mechanism might explain the capacity of sCD25 to subvert the immunostimulatory effects of CTLA-4 blockade. Both preclinical ( Figure 5 ) and clinical data ( Figure 6A-6B) indicate that the tumor growth-restraining effect of CTLA-4 blockade is compromised when the circulating sCD25 concentration is high, paralleling elevated Treg proportions. In our study, it is conceivable that sCD25 directly binds to IL-2, causing a preferential Treg amplification. In MM patients with LDH levels of > 500 IU/ml, the elevated sCD25 serum concentration had a negative prognostic impact, allowing the identification of a subset of ~25% patients that did not respond to ipilimumab ( Figure 6C ). Our data that high LDH levels (> 250 IU/ml) correlated with poor clinical outcome of ipilimumab-treated MM are in accordance with the two phase III trials leading to FDA and EMA approval of ipilimumab. Indeed, low LDH serum levels were associated with an increased OS [4, 5] . In smaller cohorts treated with ipilimumab reported by Wilgenhof et al. [57] and Delyon et al. [17] , the elevated LDH level was also negatively associated with survival. Moreover, a recent report analyzing several prognostic parameters in two European MM cohorts treated with 3 mg/kg of ipilimumab concluded that an LDH level of > 2 folds above the normal range correlated with clinical failure of CTLA4 blockade [58] . Nevertheless these retrospective results must be confirmed in prospective studies before we can test whether MM patients with high sCD25 and LDH serum concentrations should receive agents targeting CD25 such as radioimmunoconjugates or immunotoxins [59] . Altogether, we anticipate that the critical role of IL-2/ IL-2R signaling in the regulation of ipilimumab action would have major clinical implications.
Materials and Methods
Patients and specimens
Patient samples (plasma or sera) were provided by the Gustave Roussy Institute (Villejuif, France), the Memorial Sloan-Kettering Cancer Center (New York, USA), the Siena University Hospital (Siena, Italy), the German Cancer Research Center (Heidelberg, Germany), the Poznan University of Medical Sciences (Poznan, Poland) and the Essen University Hospital (Essen, Germany). Clinical responses were classified according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and the immune-related response criteria (irRC) (Supplementary information, Table S1 ). The immunomonitoring studies on fresh PBMCs were prospectively conducted on 27 patients.
Serum levels of sCD25 and sLAG3
Serum sCD25 and sLAG3 concentrations were measured using the sIL-2 Receptor EIA Kit (Beckman Coulter, Miami, FL, USA) and the sLAG3 Duo set (R&D systems, Minneapolis, MN, USA). Patient sera (or plasma) were collected before treatment and after the first and the second ipilimumab administrations. 
Quantitative reverse-transcription PCR
CD25
+ ICOS − and CD8 + T-cell populations were sorted by flow cytometry (BD Influx and BD ARIA III with FACSDiva software) from murine spleens and tumors and placed in RLT buffer (Qiagen, Hilden, Germany) containing 1% 2-mercaptoethanol, followed by their storage at −80 °C. Total cellular RNA was isolated with the RNeasy kit from Qiagen. All samples were treated with DNase using the RNase-free DNase Set (Qiagen) during the total RNA isolation. First-strand complementary DNA (cDNA) was synthesized from 5 µg of total RNA with SuperScript III reverse transcriptase and random primers (Promega, Madison, WI, USA). Expression of il-2, il-10 and egr-2 genes was analyzed by means of TaqMan Gene Expression Assays using the Universal Master Mix II (with UNG) (both from Applied Biosystems, Foster City, CA, USA), on a StepOnePlus Real-Time PCR System (Applied Biosystems). All Taqman primers were purchased from Life Technologies using FAM-TAMRA probes. Assay IDs were as follows: IL-2: Mm00434256_m1; IL-10: Mm00439614_m1; Egr-2: Mm00456650_m1; PPIA: Mm03302254_g1. Quantitative RT-PCR data were invariably normalized to the expression levels of the housekeeping gene peptidylprolyl isomerase A (Ppia). Quantification of fold changes was calculated using untreated samples as the control.
Mice
Mice aged between 7 and 12 weeks were used. Female C57BL/6J mice were obtained from Harlan (Gannat, France). Ifnar1 −/− C57BL/6J mice were kindly provided by Gilles Uzé (UMR 5235, Montpellier Fance). Mice were maintained in specific pathogen-free conditions at the Institut Gustave Roussy (IGR, Villejuif, France), the Peter MacCallum Cancer Center (East Melbourne, Australia) or the QIMR Berghofer Medical Research Institute and housed in a temperature-controlled environment with 12 h lightdark cycle and received food and water ad libitum. Experiments were carried out in compliance with French and European laws and regulations of the Peter MacCallum and QIMR Berghofer Animal Experimentation Ethics Committees. 
Cell culture and reagents
OVA-expressing mouse fibrosarcoma MCA205 cells (class I  MHC H-2 b , syngenic for C57BL/6 mice) were cultured at 37 °C under 5% CO 2 in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, 2 mM L-glutamine and 1 mM sodium pyruvate and non-essential amino acids (Gibco-Invitrogen, Carlsbad, CA, USA). OVA-expressing MCA205 cells selected in complete medium (as above) further supplemented with 50 µg/mL hygromycin B (Invitrogen, Life Technologies). Murine colon carcinoma MC38 OVA dim cells were cultured in complete DMEM medium. 
Tumor challenge and treatment
In vivo depletion of T or NK cells
Mice were injected i.p. with 100 µg of either rat anti-mouse CD8 (clone 53-6.72) or rat anti-mouse CD4 (clone GK 1.5) 1 day before anti-CTLA-4 injection, and every 3 days during the experiment. In vivo depletion of NK cells was accomplished using anti-NK1.1 (clone PK146) at 150 µg per mouse, administered i.p. daily for 3 days before anti-CTLA-4 injection and every 2-3 days throughout the experiment. Isotype control antibodies including rat IgG (clone LTF-2 or 2A3) and mouse IgG (clone C1.18.4) were given at the same dosages as controls. All the antibodies were purchased from BioXcell.
Flow cytometry
Eight color flow cytometric analysis was performed with antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, phycoerythrin cyanin 7, peridinin chlorophyll protein cyanin 5.5, allophycocyanin cyanin 7, pacific blue or allophycocyanin. The staining was realized on splenocytes or monocellular suspensions from mouse tumors. Tumors were obtained 2 days after the third injection of anti-CTLA-4. Excised tumors were cut into small pieces and digested in RPMI medium containing Liberase at 25 µg/mL (Roche) and DNase1 at 150 UI/mL (Roche) for 30 min at 37 °C, followed by crushing the pieces on a 100 µm cell strainer. Two millions of splenocytes (after red blood cells lysis) or tumor cells were preincubated with purified anti-mouse CD16/CD32 (clone 93 purchased from eBioscience) for 15 min at 4 °C, before the membrane staining. For intracellular staining, the FoxP3 staining kit (eBioscience) was used. Dead cells were excluded using the Live/Dead Fixable Yellow dead cell stain kit (Life Technologies). Stained samples were run on a Canto II (BD Bioscience, San Jose, CA, USA) cytometer, and analyses were performed with FlowJo software (Tree Star, Ashland, OR, USA). For cytokine staining, cells were stimulated for 4 h at 37 °C with 50 ng/mL of phorbol 12-myristate 13-acetate (PMA), 1 µg/mL of ionomycin (Calbiochem) and BD Golgi STOP (BD Biosciences). Anti-CD45.2 (104), CD127 (A7R34), FoxP3 (FJK-16s), LAG3 (eBioC9B7W), ICOS (7E17G9), ICOSL (HK5.3), IL17a (eBio17B7), IFN-γ (XMG1.2), TNF-α (MP6-XT22) and isotype controls rat IgG1 (eBRG1), IgG2a (eBRG2a), IgG2b (eBRG2b) were purchased from eBioscience. Anti-CD3 (145-2C11), CD25 (PC61.5.3), IL-10 (554467), CD11b (M1/70) and rat IgG1 were obtained from BD Bioscience. Anti-CD4 (GK1.5), CD8β (YTS1567.7), CD11c (N418) and rat IgG2a (RTK2758) were purchased from Biolegend (San Diego, CA, USA). Anti-CD25 (7D4) was from Miltenyi Biotech. For cytofluorometry of human PBMCs, anti-CD3 (BW262/56) and mouse IgG1 (IS5-21F5) were purchased from Miltenyi Biotech. Anti-CD4 (SK3), CD8 (SK1), CD25 (M-A251), CD45 (J33) and mouse IgG1 (MOPC-21) were obtained from BD Bioscience. Anti FoxP3 (PCH101) was purchased from eBioscience 
Bioinformatics and statistical analysis
Data were analyzed with Microsoft Excel (Microsoft Co., Redmont, WA, USA), Prism 5 (GraphPad San Diego, CA, USA) and the environment R (R Foundation for Statistical Computing, Vienna, Austria). Data are presented as means ± SEM and p-values were computed by paired or unpaired t-tests where applicable. Tumor growth was subjected to a linear mixed effect modeling applied to log pre-processed tumor volumes [61] . The P-values were calculated by testing jointly whether both tumor growth slopes and intercepts (on a log scale) are where dissimilar between treatment groups of interests. OS determined from the first injection and irRC at the date of diagnosis/time of treatment were used as the primary end points. Likelihood ratio test (LRT) from Cox proportional hazard regression modeling was used for assessing predictors of survival (including patient characteristics), as well as the added prognostic value of sCD25. All reported tests are twotailed and were considered significant for P < 0.05. Regression models analyses were conducted on the log basis two transformed marker concentrations and were evaluated by means of Schoenfeld residuals. Therefore, hazard ratios and associated 95% confidence intervals are easily interpretable in terms of concentration doublings. For graphical representations, serum markers levels were partitioned into two out of three groups based on the observed median/tertile (sCD25, sLAG3) or a threshold of 250 (LDH).
